April Could Spark A Tech Rally For These Three Magnificent 7 Giants, If History Has A Say

Genprex, the clinical-stage gene therapy company, is gearing up for an insightful showcase at the upcoming September investor and industry conferences. As the curtains rise on this exciting stage, Genprex plans to dazzle attendees with a glimpse into its cutting-edge gene therapies designed to revolutionize the treatment landscape for cancer and diabetes.

Mark your calendars for Genprex's participation in two key events this month. The stage is set, the spotlight is waiting – will you be there to witness the magic unfold?

From September 9 to 13, 2024, Genprex's President and Chief Executive Officer, Ryan Confer, will be taking center stage in the virtual realm. A presentation brimming with insights on the company's gene therapies for cancer and diabetes will be available on-demand from September 9 to 11, 2024. Confer's virtual presence promises to captivate audiences, offering a unique opportunity for investors to delve deep into Genprex's world of innovative treatments.

For the in-person aficionados, the Westin Grand Central in New York, NY, will play host to Genprex's Senior Vice President of Intellectual Property and Licensing, Thomas Gallagher, on September 30 and October 1, 2024. Gallagher's presence promises engaging interactions with attendees, providing a firsthand glimpse into Genprex's remarkable strides in the field of genetic medicines.

With a focus on developing life-altering therapies for cancer and diabetes, Genprex's innovative technologies are primed to usher in a new era of hope for patients with limited treatment options. Collaborating with esteemed institutions, the company is at the forefront of harnessing the power of gene therapy to cater to a broad patient base eagerly awaiting novel treatment approaches.

Genprex's cutting-edge oncology program utilizes the Oncoprex® Delivery System, a non-viral platform that encapsulates gene-expressing plasmids within lipid-based nanoparticles. This ingenious system, administered intravenously, propels tumor cells to express vital tumor suppressor proteins, effectively targeting deficiencies within the tumor.

The Company's lead product candidate, Reqorsa® Gene Therapy, is currently undergoing evaluation in clinical trials targeting Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). With FDA Fast Track Designations under its belt, Genprex's lung cancer programs are making waves in the treatment landscape, redefining standards and ushering in a new dawn of hope for patients.

But the story doesn't end there. Genprex's foray into diabetes gene therapy unfolds a novel infusion process. By employing an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas, the company's GPX-002 treatment promises transformative results. The treatment aims to rejuvenate and replenish beta cells, offering potential respite to patients grappling with Type 1 and Type 2 diabetes.

As Genprex paves the way for groundbreaking advancements in gene therapy, investors and stakeholders are invited to join this transformative journey. By engaging with the Company through press releases, industry updates, and social media channels, individuals can stay abreast of Genprex's trailblazing initiatives.

Excitement is in the air as Genprex prepares to enlighten, engage, and inspire at the upcoming conferences. Are you ready to be part of this extraordinary voyage into the future of gene therapies? The stage is set, the lights are dimming – it's time to witness history in the making.